Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage ADC biotech with ValiLinker site-specific conjugation technology; VLT-03 in Phase I for solid tumors and VLT-01 for brain metastases with $20.5M raised.
Valink Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for solid tumors using its proprietary ValiLinker technology — a site-specific conjugation platform that precisely attaches cytotoxic payloads to antibodies at defined positions, improving ADC stability, homogeneity, and therapeutic index compared to conventional random-conjugation approaches. Founded in 2020 and headquartered in Houston, Texas, Valink raised $20.5 million total including an $11.8 million Pre-Series A in October 2025 to advance its pipeline into clinical trials.\n\nValink's pipeline centers on VLT-03 (targeting solid tumors in Phase I trials) and VLT-01 (targeting solid tumors with brain metastases, addressing the significant unmet need in CNS-penetrating oncology therapeutics). The ValiLinker conjugation technology enables precise drug-to-antibody ratios and reduces off-target toxicity that has historically limited ADC tolerability — the platform differentiates Valink from earlier ADC developers by addressing the conjugation chemistry precision that drives therapeutic index improvements in this modality.\n\nIn 2025, Valink competes in the ADC space with Seagen (acquired by Pfizer), ImmunoGen (acquired by AbbVie), Daiichi Sankyo (partnered with AstraZeneca), and numerous clinical-stage biotech ADC developers. ADC development has become one of the most active areas in oncology after the commercial success of Enhertu (trastuzumab deruxtecan) demonstrated the potential of the modality. Valink's site-specific conjugation differentiation targets the technical limitations of first-generation ADCs that created toxicity issues. The 2025-2026 strategy focuses on Phase I dose escalation for VLT-03, building clinical proof-of-concept for the ValiLinker platform, and positioning for partnership or licensing discussions with large pharma.
$2.3B raised at $29.3B valuation; $2B+ ARR (Q1 2026); used by 50%+ of Fortune 500. Dominant commercial AI coding tool; built on VSCode fork with native agent mode. Competing with GitHub Copilot, Windsurf, and Lovable in the vibe-coding wave.
Cursor is an AI-powered code editor built on Visual Studio Code that integrates advanced language models to provide intelligent code completion, generation, debugging, and refactoring capabilities directly in the development workflow. The company serves software developers seeking to accelerate coding productivity through AI assistance while maintaining full control and understanding of their code. Cursor delivers value through contextual code suggestions that understand entire codebases, natural language commands to modify code, inline AI chat for explaining complex code, and a familiar VS Code interface that requires minimal learning curve for existing developers.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.